抗抑郁药联合用药以及其他干预策略治疗难治性抑郁症的评价(英文) 被引量：4

Evaluation of antidepressant polypharmacy and other interventions for treatment-resistant depression

下载PDF

导出

摘要有关难治性抑郁症(treatment-resistant depression,TRD)的定义及其亚类一直有争议,从而难以评估治疗这种慢性致残性病症的不同方案的疗效。根据TRD的症状严重程度等临床特征以及人口学特征方面进行分类可能有助于对同一亚类TRD的识别,并有助于制定针对特定亚类的干预措施。 There is on-going controversy about the definition and sub-classification of treatment-resistant depression （TRD） that makes it difficult to assess the effectiveness of different proposed strategies for treating this chronic, often disabling condition. Sub-classification of TRD in terms of symptom severity and in terms of demographic and clinical characteristics may help in the recognition of homogeneous TRD subgroups and in the development of subgroup-specific interventions.

作者彭代辉方贻儒

机构地区 Division of Mood Disorders

出处《上海精神医学》 2014年第6期365-367,共3页 Shanghai Archives of Psychiatry

基金 supported by the National Natural Science Foundation of China(91232719) the '12th Five-year Plan’of National Key Technologies R&D Program(2012BAI01B04) the National Key Clinical Disciplines at Shanghai Mental Health Center(OMA-MH,2011-873) the Science Fund of Shanghai Jiao Tong University(YG2012MS11) Fund of the Science and Technology Commission of the Shanghai Municipality(134119a6200)

关键词难治性抑郁症分类辅助治疗联合治疗 treatment-resistant depression classification adjunctive treatment combined treatment

分类号 R749.4 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献10

1Lopez AD, Murray CC. The global burden of disease, 1990- 2020. Nat Med. 1998; 4 (11): 1241-1243. doi: http://dx.doi. org/10.1038/3218.
2Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002; 63(2): 95-103.
3Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lencet. 2013; 381(9882): 1987-2015. doi: http://dx.doi.org/10.1016/ S0140-6736(13)61097-1.
4[EMACPMP] The European agency for the evaluation of medical products committee for proprietary medical products. Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Depression. Report: CPMP/EWP/518/97. 2002; 4:4.
5Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005; 25(4): 336-341.
6Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997; 58(Supp113): 23-29.
7Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003; 53: 649-659. doi: http:// dx.doi.org/10.2026/S0006-3223(03)00231-2.
8Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002; 36(3): 384-391. doi: http://dx.doi.org/10.1046/j.1440- 1614.2001.01026.x.
9Liu FR, Xia YP, Zhang JX. [Case-control study of paroxetine with small doses of olanzapine in the treatment of depression]. Shanghai Arch Psychiatry. 2005; 5: 13-15. Chinese.
10Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008; 8(9): 1299-1306.